Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)-Reference-Cited by-同舟云学术

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)

Published:2016-09-13 Issue:1 Volume:31 Page:34-39
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Blum W,Sanford B L,Klisovic R,DeAngelo D J,Uy G,Powell B L,Stock W,Baer M R,Kolitz J E,Wang E S,Hoke E,Mrózek K,Kohlschmidt J,Bloomfield C D,Geyer S,Marcucci G,Stone R M,Larson R A,

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu2016252.pdf

Reference37 articles.

1. Champlin R, Jacobs A, Gale RP, Boccia R, Elashoff R, Foon K et al. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Lancet 1984; 1: 894–896.

2. Raza A, Preisler HD, Browman GP, Larson RA, Rustum YM, Goldberg J et al. Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. Leuk Lymphoma 1993; 10: 57–66.

3. Sauter C, Berchtold W, Fopp M, Gratwohl A, Imbach P, Maurice P et al. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1984; 1: 379–382.

4. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480–2489.

5. Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21: 4496–4504.

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study;Annals of Hematology;2024-01-26

2. Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia;Hematology;2023-11-02

3. HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia;Hematology;2023-07-05

4. Maintenance therapy in acute myeloid leukemia: advances and controversies;Haematologica;2023-05-04

5. Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE);Cancers;2023-04-24